My Take From ACR 2019: Safety Data on JAK Inhibitors
  • CME

November 8-13, 2019; Atlanta, Georgia
MACE and VTE data were presented for all approved and phase III JAK inhibitors.
Stanley B. Cohen, MD
Physicians: maximum of 0.25 AMA PRA Category 1 Credits
Released: December 5, 2019 Expiration: December 4, 2020

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply efficacy, safety, and patient-reported outcomes data from studies of new and emerging agents for RA to the care of patients now and in the future
  • Identify key findings from real-world experience in the management patients with RA who have failed or become intolerant to TNF inhibitors
  • Describe outcomes from RA studies of biologic and targeted DMARD therapy initiated early in the disease course
Provided by the Annenberg Center for Health Sciences at Eisenhower
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Supported by educational grants from
Gilead Sciences
Mallinckrodt Pharmaceuticals

Information on this Educational Activity

The Annenberg Center assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME/CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Stanley B. Cohen, MD

Clinical Professor
Department of Internal Medicine
University of Texas Southwestern Medical School
Co-Director
Division of Rheumatology
Presbyterian Hospital
Co-Medical Director
Metroplex Clinical Research Center
Dallas, Texas

Stanley B. Cohen, MD, has disclosed that he has received consulting fees and funds for research support from AbbVie, Amgen, Gilead Sciences, Lilly, and Pfizer.

The PIM planners and managers have nothing to disclose.

Charles E. Willis, Director of Continuing Education; Amanda Sewell, MBA, Manager of Continuing Education and Melissa Velasquez, Accreditation Specialist from the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Annenberg Center, Postgraduate Institute for Medicine (PIM), Clinical Care Options, and activity supporters do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Annenberg Center, PIM, Clinical Care Options, and activity supporters. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for rheumatologists and other healthcare providers who care for patients with rheumatoid arthritis.

Goal

The goal of this program is to improve participants’ knowledge and competence in translating the most clinically important data from ACR/ARP 2019 into practical management strategies for patients with RA.

Physician Continuing Medical Education

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 05, 2019, through December 04, 2020:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Expert commentary on real-world and trial data on treating RA after failing biologic and targeted small-molecule DMARDs, from EULAR 2020 by CCO

Eric M. Ruderman, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: August 27, 2020 Expired: August 26, 2021

Expert commentary on key studies in RA comorbidities from EULAR 2020 as reported by CCO

Paul Emery, MA, MD, FRCP Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: August 24, 2020 Expired: August 23, 2021

EULAR 2020 on SELECT-CHOICE: upadacitinib vs abatacept for active rheumatoid arthritis with prior inadequate response or intolerance to bDMARDs as reported by CCO

Released: August 17, 2020

New from EULAR 2020, Clinical Care Options (CCO): adults with immune-mediated inflammatory disease report biologic-associated fatigue in Dutch Biologic Monitor

Released: August 13, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue